BNND Stock Overview
Engages in the research and development of Bio-based products and solutions in Germany, the United States, France, the Netherlands, and the United Kingdom. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
BRAIN Biotech AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €5.86 |
| 52 Week High | €6.08 |
| 52 Week Low | €5.86 |
| Beta | 1.44 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | -45.74% |
| 5 Year Change | n/a |
| Change since IPO | -61.80% |
Recent News & Updates
Recent updates
Shareholder Returns
| BNND | GB Chemicals | GB Market | |
|---|---|---|---|
| 7D | 0% | 0.9% | 1.7% |
| 1Y | n/a | -17.6% | 8.3% |
Return vs Industry: Insufficient data to determine how BNND performed against the UK Chemicals industry.
Return vs Market: Insufficient data to determine how BNND performed against the UK Market.
Price Volatility
| BNND volatility | |
|---|---|
| BNND Average Weekly Movement | n/a |
| Chemicals Industry Average Movement | 5.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: BNND has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine BNND's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 312 | Aryan Moelker | www.brain-biotech.com |
BRAIN Biotech AG researches, develops, produces, and markets enzymes, biocatalysts, microorganisms, and bioactive natural substances for chemical industries in Germany, the United States, France, the Netherlands, and the United Kingdom. The company operates in two segments, BioScience and BioIndustrial. It identifies and develops bioactive natural compounds, including sugar substitutes and taste modulators, and nature-based active ingredients for product development in the food, animal feed, skin care, cosmetics, and chemical industries.
BRAIN Biotech AG Fundamentals Summary
| BNND fundamental statistics | |
|---|---|
| Market cap | €130.21m |
| Earnings (TTM) | -€8.23m |
| Revenue (TTM) | €47.53m |
2.7x
P/S Ratio-15.8x
P/E RatioIs BNND overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BNND income statement (TTM) | |
|---|---|
| Revenue | €47.53m |
| Cost of Revenue | €21.22m |
| Gross Profit | €26.31m |
| Other Expenses | €34.54m |
| Earnings | -€8.23m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.38 |
| Gross Margin | 55.35% |
| Net Profit Margin | -17.31% |
| Debt/Equity Ratio | 0% |
How did BNND perform over the long term?
See historical performance and comparison